Long-term use of non-steroidal anti-inflammatory drugs in the treatment of axial spondylitis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents relevant data on the main principles and recommendations for the management and treatment of patients with axial spondyloarthritis (axSpA). Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line drugs prescribed for axSpA. The effect of NSAIDs on the activity and radiological progression of axSpA is described in detail. From the perspective of a balance of efficacy and safety profile of NSAIDs, patients with axSpA can use selective COX-2 inhibitor etoricoxib (Arcoxia®) for a long time; it has been well studied with prolonged use and has a large base of research with a high degree of evidence.

Full Text

Restricted Access

About the authors

Sh. F Erdes

V.A. Nasonova Research Institute of Rheumatology

Laboratory of Spondyloarthritis and Psoriatic Arthritis

Daria G. Rumiantceva

V.A. Nasonova Research Institute of Rheumatology

Email: rumiantceva01@gmail.com
PhD, Junior Reseracher at the Laboratory of Spondyloarthritis and Psoriatic Arthritis

References

  1. Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Curr OpinRheumatol. 2010;22(4):375-80. Doi: 10.1097/ bor.0b013e32833ac5cc
  2. Подряднова М.В., Балабанова РМ., Урумова М.М., Эрдес Ш.Ф. Взаимосвязь клинических характеристик анкилозирующего спондилита с трудоспособностью и производительностью труда. Научно-практическая ревматология. 2014;52(5):513-19. Doi: https://doi.org/10.14412/1995-4484-2014-513-519. Doi: https:// doi.org/10.14412/1995-4484-2014-513-519.
  3. Smolen J.S., Schols M., Braun J., et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheumatic Dis. 2018;77:3-17. doi: 10.1136/annrheumdis-201 7-211734.
  4. Гайдукова И.З., Ребров А.П., Коротаева Т. В. и др. Ремиссия при аксиальных спондилоартритах - определение и инструменты оценки (рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России»). Научно-практическая ревматология. 2018;56(1):10-14. Doi: https://doi.org/10.14412/1995-4484-2018-10-14. Doi: https://doi. org/10.14412/1995-4484-2018-10-14.
  5. Van der Heijde D., Ramiro S., Landewe R., et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases. 2017;76(6):978-91. Doi: https://doi. org/10.1136/annrheumdis-2016-210770.
  6. Гайдукова И.З., Ребров А.П., Лапшина С.А. и др. Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научнопрактическая ревматология. 2017;55(5): 474-84.
  7. van der Heijde D., Baraf H.S., Ramos-Remus C., et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005;52:1205e15. doi: 10.1002/art.20985.
  8. Sari I., Ozturk M.A., Akkoc N. Treatment of ankylosing spondylitis. Turk J. Med Sci. 2015;45:416e30.
  9. Kroon F., Burg L., Ramiro S., et al. Non-steroidal anti-inflammatory drugs in axial spondyloarthritis: a Cochrane review. J. Rheumatol. 2014;43:607-17. Doi: http://dx.doi.org/10.3899/jrheum.150721.
  10. Wong R.S.Y. Disease-Modifying Effects of LongTerm and Continuous Use of Nonsteroidal AntiInflammatory Drugs (NSAIDs) in Spondyloarthritis. Advan Pharmacol Sci. 2019;2019. Doi: https:// doi.org/10.1155/2019/5324170
  11. Simon D.L., Botting R.M., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387-437. doi: 10.1124/pr.56.3.3.
  12. Warner T.D., Mitchel J.A. Cycloxygenase: new isoforms, new inhibitors, and new lessons from clinic. FASEB J. 2004;18:790-804.
  13. Rao P., Knaus E.E. Evolution of nonsteroidal antiinflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm Pharmaceut Sci. 2008;11(2):81-110.
  14. Sanchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A., Gonzalez-Aveledo L. Hypersensitivity reactions to nonsteroidal anti-Inflammatory drugs: an update. Pharmaceuticals. 2010;3(1):10-8. Doi: https://doi.org/10.3390/ph3010010.
  15. Bakland G., Gran J.T., Nossent J.C. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70:1921 25. doi: 10.1136/ard.2011.151191
  16. Haroon N.N., Paterson J.M., Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015;163:409-16. doi: 10.7326/M14-2470.
  17. Wang R., Dasgupta A., Ward M.M. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016;75:1152-60. Doi: 10.1136/ annrheumdis-2015-207677.
  18. Sieper J., lenaerts J., Wollenhaupt J., et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axia spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73:101-7l.
  19. Kroon F, Burg L., Ramiro S., et al. Non-steroidal anti-inflammatory drugs in axial spondyloarthritis: a Cochrane review. J Rheumatol. 2014;43:607 17. Doi: http://dx.doi.org/10.3899/jrheum. 150721
  20. Tang M., et al. Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients. Clinil Rheumatol. 2018;37(1): 245-50.
  21. Wanders A, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis & Rheumatism. 2000;02(6):1706 60. doi: 10.1002/art.21004
  22. Kroon F., Landewe R., Dougados M., et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:1623-29. Doi: 10.1136/ annrheumdis-2012-201370.
  23. Poddubnyy D., Rudwaleit M., Haibel H., et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71:1616-22. Doi: 10.3899/ jrheum.100721.
  24. Румянцева Д.Г., Дубинина Т. В., Эрдес Ш.Ф. Влияние частоты приема нестероидных противовоспалительных препаратов на рентгенологическое прогрессирование сакроилиита у пациентов с ранним аксиальным спондилоартритом. Научно-практическая ревматология. 2018;06(3):346-00.
  25. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научнопрактическаяревматология. 2018;06:1-29. Doi: https://doi.org/10.14412/1990-4484-2018-1 29
  26. Sostres C., Gargallo C.J., Arroyo M.T., Lanas A. Adverse effects of non-steroidal antiinflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(2):121-32. doi: 10.1016/j.bpg.2009.11.000.
  27. Kivitz A.J., Nayiager S., Schimansky T., et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Therapeut. 2004;19(11);1189-98. doi: 10.1111/j.1360-2036.2004.01906.x.
  28. Whittle B.J.R. The potentiation of taurocholate-induced rat gastric erosions following parenteral administration of cyclooxygenase inhibitors. Br J Pharmacol. 2012;80(3):040-01.
  29. Peskar B.M. Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing. Inflammopharmacology. 2000;13(1-3):10-26.
  30. Каратеев А.Е. и др. Эндоскопическая картина верхних отделов желудочно-кишечного тракта на фоне приема различных НПВП. Клиническая фармакология и терапия. 2018;4.
  31. Fournier J.-P, Sommet A., Bourrel R., et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study Eur J Clin Pharmacol. 2012;68:1033-40. Doi: 10.1007/ s00228-012-1283-9.
  32. John C.M., Shukla R., Jones C.A. Using NSAID in volume depleted children can precipitate acute renal failure. Arch Dis Childhood. 2007;92(6):024-26. doi: 10.1136/adc.2006.103064.
  33. Mackenzie I.S., MacDonald T.M. Treatment of osteoarthritis in hypertensive patients. Exp Opin Pharmacother. 2010;11(3):393-403.
  34. Harirforoosh S., Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Exp Opin Drug Saf. 2009;8(6):669-81. doi: 10.1017/14740330903311023.
  35. Zingler G., Hermann B., Fischer T., Herdegen T. Cardiovascular adverse events by nonsteroidal anti-inflammatory drugs: when the benefits outweigh the risk. Exp Rev Clin Pharmacol. 2016;9(11):1479-92. doi: 10.1080/17012433.2016.1230490.
  36. Harirforoosh S., Asghar W., Jamali F Adverse effects of nonsteroidal anti-inflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharmaceutl Sci. 2013;16(0):821-47.
  37. Whelton A. Nephrotoxicity of nonsteroidal antiinflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(2):13S-34S. doi: 10.1016/s0003-9343(99)00113-8.
  38. Dixit M., Nguyen C., Carson T., et al. Nonsteroidal antiinflammatory drugs-associated acute interstitial nephritis with granular tubular basement membrane deposits. Paediatr Nephrol. 300-;33()):)42-4-. doi: 10.1007/s00467-007-0080-0.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies